Gyre Therapeutics, Inc.
GYRE
$6.68
$0.142.14%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.12% | -20.09% | 33.45% | 19.92% | 17.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.12% | -20.09% | 33.45% | 19.92% | 17.88% |
| Cost of Revenue | 91.92% | 37.25% | 48.09% | 69.94% | 49.48% |
| Gross Profit | -5.90% | -21.81% | 32.80% | 17.96% | 16.88% |
| SG&A Expenses | -3.79% | 27.66% | 36.72% | 12.13% | 25.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.38% | 32.08% | 36.26% | 11.21% | 45.58% |
| Operating Income | -518.79% | -595.28% | -81.90% | 63.62% | -168.67% |
| Income Before Tax | -816.44% | -408.73% | -108.55% | 94.12% | -126.10% |
| Income Tax Expenses | -124.77% | -39.07% | 540.39% | 57.64% | -55.78% |
| Earnings from Continuing Operations | -537.91% | -476.17% | -340.07% | 107.84% | -149.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 29.28% | 4,435.08% | 46.56% | -34.30% | 380.69% |
| Net Income | -1,873.41% | -316.91% | -1,640.40% | 221.17% | -83.05% |
| EBIT | -518.79% | -595.28% | -81.90% | 63.62% | -168.67% |
| EBITDA | -905.52% | -487.33% | -29.92% | 61.93% | -135.27% |
| EPS Basic | -406.11% | -666.54% | -1,475.00% | 203.05% | -155.45% |
| Normalized Basic EPS | -340.87% | -72.84% | -237.93% | 216.47% | -36.59% |
| EPS Diluted | -374.31% | -14,290.00% | -541.18% | 166.41% | -521.67% |
| Normalized Diluted EPS | -342.03% | -72.77% | -237.93% | 230.99% | -24.45% |
| Average Basic Shares Outstanding | 12.92% | 6.90% | 6.05% | 6.08% | 4.23% |
| Average Diluted Shares Outstanding | 12.82% | 6.67% | 6.05% | 1.30% | -12.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |